BioCentury | Aug 19, 2020
Product Development

Launch of generic Tecfidera puts more pressure on Biogen’s pipeline

The introduction of generic competition in the U.S. for MS blockbuster Tecfidera, which accounted for 40% of Biogen’s product revenue last half, puts increased pressure on the remainder of big biotech’s pipeline.  On Wednesday, Mylan...
BioCentury | Jul 31, 2020

Gilead expects remdesivir to drive P&L rebound by year-end

Gilead bumped up its full year guidance Thursday after projecting to manufacture 2 million treatment courses of its COVID-19 antiviral remdesivir by year-end, and sell 1-1.5 million courses even as the company reported 2Q20 earnings...
BioCentury | Feb 5, 2020
Product Development

Biogen investors look ahead to Alzheimer’s after Tecfidera IP win

The U.S. Patent Trial and Appeal Board removed a major overhang for Biogen investors on Wednesday after ruling to uphold the validity of a patent covering blockbuster MS therapy Tecfidera dimethyl fumarate. The news sent...
BioCentury | Dec 10, 2019
Company News

Janssen pays $750M for XBiotech's dermatology candidate after positive Phase II data

...who have natural immunity against specific diseases. Outside of IL-1α, XBiotech's pipeline includes clinical antibody 514G3...
BioCentury | Nov 13, 2019
Clinical News

Bardoxolone data set Reata up to advance second compound toward registration

Weeks after regaining rights to cardiorenal compounds from AbbVie, Reata has reported its second pivotal trial success of the quarter, paving the way for global marketing applications for its two most advanced compounds as it...
BioCentury | Oct 30, 2019
Financial News

Pfizer surprises Street with Vyndaqel sales, uptake

Uptake of Pfizer's Vyndaqel tafamidis in 3Q19 surpassed a consensus estimate following its approval in May, adding to expectations for a drug the pharma has already touted as a potential blockbuster to treat transthyretin-mediated amyloid...
BioCentury | May 11, 2019

Earnings on deck

Earnings on deck At least five profitable biotechs and pharmas are slated to report earnings this week. (A) Fiscal 4Q; (B) Full-year EPS Company Date Pre/post mkt 1Q19 EPS est 1Q18 EPS Expected chg Eisai...
BioCentury | Feb 15, 2019
Company News

PTAB to review Biogen's Tecfidera patent

The U.S. Patent Trial and Appeal Board will review a patent held by Biogen Inc. (NASDAQ:BIIB) covering methods of treating multiple sclerosis with Tecfidera dimethyl fumarate. Mylan N.V. (NASDAQ:MYL) filed the inter partes review (IPR)...
BioCentury | Jan 5, 2019

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Sep 28, 2018
Financial News

Arvinas raises $120M in IPO

Arvinas Inc. (NASDAQ:ARVN) raised $120 million late Sept. 26 through the sale of 7.5 million shares at $16 in its bumped-up IPO. The price, at the top of its proposed $14-$16 range, values the company...
Items per page:
1 - 10 of 314